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Amyloid peptide is able to promote the activation of microglia and astrocytes in
Alzheimer’s disease (AD), and this stimulates the production of pro-inflammatory
cytokines. Inflammation contributes to the process of neurodegeneration and therefore
is a key factor in the development of AD. Some of the most important proteins
involved in AD inflammation are: clusterin (CLU), complement receptor 1 (CR1),
C reactive protein (CRP), tumor necrosis factor α (TNF-α), the interleukins 1α
(IL-1α), 6 (IL-6), 10 (IL-10) and cyclooxygenase 2 (COX-2). In particular, COX-2
is encoded by the prostaglandin-endoperoxide synthase 2 gene (PTGS2). Since
variations in the genes that encode these proteins may modify gene expression
or function, it is important to investigate whether these variations may change the
developing AD. The aim of this study was to determine whether the presence of
polymorphisms in the genes encoding the aforementioned proteins is associated
in Mexican patients with AD. Fourteen polymorphisms were genotyped in 96
subjects with AD and 100 controls; the differences in allele, genotype and haplotype
frequencies were analyzed. Additionally, an ancestry analysis was conducted to
exclude differences in genetic ancestry among groups as a confounding factor
in the study. Significant differences in frequencies between AD and controls were
found for the single-nucleotide polymorphism (SNP) rs20417 within the PTGS2
gene. Ancestry analysis revealed no significant differences in the ancestry of the
compared groups, and the association was significant even after adjustment for
ancestry and correction for multiple testing, which strengthens the validity of
the results. We conclude that this polymorphism plays an important role in the
development of the AD pathology and further studies are required, including their
proteins.
Keywords: Alzheimer’s disease, inflammation, prostaglandin-endoperoxide synthase, cyclooxygenase 2, genetic
ancestry
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease which
major symptom is the impairment of memory and other
cognitive functions (Collette et al., 1999; Di Paola et al.,
2007). It has been estimated that the global prevalence of
dementia is around 4.5% and that AD accounts for 65% of
the total number of dementia Alzheimer’s type (DAT; Kalaria
et al., 2008; Rizzi et al., 2014), which places AD as the
major global cause of dementia. The prevalence of dementia
varies considerably around the world. There are few studies
particularly in Mexico, however it has been determined that
in Mexican population above 20 years old the prevalence of
dementia is 6.1–7.9%, and the country was reported to be
the fifth with the highest prevalence of the disease in Latin
America (Llibre Rodriguez et al., 2008; Prince et al., 2008; Mejia-
Arango and Gutierrez, 2011; Ramírez-Díaz et al., 2015). AD is
a complex disease which etiology relies both in environmental
and genetic factors, but its exact causes are unknown to date.
The definitive diagnose of AD can be only performed by
post mortem histological analysis, in which certain distinctive
lesions must be found. These lesions consist of protein aggregates
known as neuritic plaques (NPs), composed of the amyloid-β
peptide (Wong et al., 1985), and neurofibrillary tangles (NFTs),
composed of hyperphosphorylated tau protein (Kosik et al.,
1986).
In AD the neuroinflammation is an early and continuous
feature of the disease (Hensley, 2010; McGeer andMcGeer, 2010;
Zhang and Jiang, 2015). It has been reported that the activation of
the immune system, which leads to a general inflammatory state
in the brains, one of the major and most constant characteristics
of AD, as well as other neurodegenerative diseases (Meraz-
Ríos et al., 2013). This response involves cellular and molecular
changes, the recruitment of peripheral immune cells (Rezai-
Zadeh et al., 2011), and the release of inflammatory mediators
in the brain (Heneka et al., 2010).
Several studies in animal models have confirmed that the
presence of Aβ in the brain leads to the activation of microglial
cells and astrocytes (Frautschy et al., 1992; Hanzel et al., 2014).
The high levels of chemokines and chemokine receptors in brain
regions surrounding NPs suggest that there is a chemotactic
migration of microglia towards Aβ peptides (Walker et al.,
2006). The activation of astrocytes and microglia leads to
an increased secretion of pro-inflammatory proteins, such as
cyclooxygenases, complement proteins and their receptors, acute
phase proteins, adhesion molecules, chemokines, and cytokines
(Liao et al., 2004; Ramesh et al., 2013). The chronic increased
secretion of this proteins leads to increased oxidative stress
and enhances cell death, which leads to neurodegeneration
in the central nervous system (CNS; Meraz-Ríos et al.,
2013).
It has been proposed that sequence variations in the genes
that code pro-inflammatory and anti-inflammatory proteins
might play a role changing the function or expression rate
of the proteins and in this way modifying the inflammatory
response in the brain; this could have an effect in the
risk of developing AD. We selected 14 single-nucleotide
polymorphisms (SNPs), according to the Alzgene Top results.
Numerous studies have examined the presence of SNPs in
genes of proinflammatoy cytokines such as Interleukin-1α (IL-
1α; Combarros et al., 2002), Interleukin 6 (IL-6; Chen et al.,
2012), Tumor Necrosis Factor α (TNF-α; Laws et al., 2005;
Ardebili et al., 2011) and in the anti-inflammatory Interleukin
10 (IL-10; Bagnoli et al., 2007), whose production have found
altered in CSF and peripheral blood in AD patients (Blum-
Degen et al., 1995; Swardfager et al., 2010). The promoter
region SNPs of TNF gene, rs1800629 and rs1799724, have
been studied for a possible involvement with a functional
alteration in the production of this proinflammatory cytokine,
in particular the presence of the rs1799724 in Caucasians
with a diagnosis of probable AD, correlated with altered
levels of Aβ42 in CSF (Laws et al., 2005). IL1A is another
candidate gene associated with AD (Combarros et al., 2002);
in this case we selected the rs17561 variant, which has been
previously studied in Americans and Japanese populations
(Minster et al., 2000; Yucesoy et al., 2006). As for the
anti-inflammatory cytokines, the most studied polymorphisms
are rs1800871, rs1800896, rs1800872; they are located in
the promoter region of IL10 gene and have been related
with an alteration of transcriptional activation with a gene-
dosage related effect and have replicated an association in
Caucasian populations (Bagnoli et al., 2007; Combarros et al.,
2009). Also, a possible interaction within these SNPs and the
variants on the IL6 gene was reported (Combarros et al.,
2009).
In the same way, some polymorphisms on Clusterin (CLU)
and Complement Receptor 1 (CR1) genes have shown a
consistent association with AD in genome-wide association
studies (GWAS; Harold et al., 2009; Lambert et al., 2009; Jun
et al., 2010; Hu et al., 2011). Another protein that has been linked
with the inflammatory process in AD is the c-reactive protein
(CRP). This acute phase reactant has been found in association
with plaques and NFTs (Yasojima et al., 2000). Also, elevated
tissue levels of CRP have been related with an increased risk
for developing AD; however when the disease has established,
the CRP levels decrease (Schmidt et al., 2002; O’Bryant et al.,
2013). For these reasons, this protein has been proposed as
an early biomarker for AD. Moreover, SNPs on CRP gene
like rs1130864 and rs1800947 have been involved with altered
CRP levels (Kok et al., 2011) and with a possible association
with AD in Caucasians (Flex et al., 2004; van Oijen et al.,
2007). Additionally, the cyclooxygenase-2 (COX-2) is encoded
by the prostaglandin-endoperoxide synthase 2 gene (PTGS2);
this enzyme involved in neuroinflammation, is responsible
for prostaglandins (PG’s) synthesis. It has been documented
that COX-2 expression increases in the hippocampus of AD
brain, which also correlates to the severity of the pathology
(Ho et al., 2001; Meraz-Ríos et al., 2013). Due to this
fact, polymorphisms in the PSTG2 gene have been studied;
mainly, the rs20417 located in the promoter region has shown
an association with decreased risk of AD (Abdullah et al.,
2006).
Recently, publications related to the presence of
polymorphisms associated with the development of AD
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have increased; however, numerous lines of evidence
have demonstrated discrepant results among populations.
These findings suggest that it is necessary to reduce the
confounding factors and focus on identifying the cause (Jiang
et al., 2013). The vast majority of these studies have not
evaluated the role of individual differences in ancestry as a
confounding factor in their study population. Mexican and
other Latin American populations are the result of mixed
breeding among three ancestral populations: Amerindian,
Caucasian and African. Intra or inter-group differences
in genetic ancestry might represent a source of spurious
associations in case-control studies if they are not appropriately
regarded.
Considering all of the above mentioned, the aim of this
study was to evaluate a set of candidate polymorphisms in
inflammation-related genes, and to determine whether they
are associated with the risk of developing AD in the Mexican
population, considering the genetic ancestry of the study
subjects.
Materials and Methods
Study Population
The subjects were patients with a clinical diagnose of dementia
of the Alzheimer-type (DAT), or cognitively healthy subjects
(controls). All subjects were Mexican, with Mexican ancestry
back to the third generation, and at least 60 years old at
the sampling date. This work was carried out according
with the ethical standards of the Committee on Human
Experimentation of the institution (Instituto Nacional de
Neurología y Neurocirugía Number 100/07) in accord with
the Helsinki Declaration of 1975. A Student’s t test was done
comparing the parameters of mean age between cases and
controls.
Ninety four DAT patients, previously diagnosed by a group
of Geriatricians and Neurologists, were included according to
the NINCDS-ADRDA (Mckhann et al., 1984) criteria. The DAT
patients were interviewed at their scheduled visits at Geriatric
Clinic of the General Hospital Mocel in Mexico City and
Geriatric Center in Querétaro.
The inclusion criteria were: (1) patients with DAT were
required to be able to read and write; (2) patients have to
be 60 years old and over; and (3) they had to hand in an
informed consent sheet signed by both the informant and
the elderly person. The exclusion criteria were as follows:
(1) acute and/or exacerbated chronic disease present within
30 days before the interview that could affect the quality
of response to questionnaires, according to the medical
staff of the study; (2) decreased alertness (for any cause);
(3) severe aphasia; (4) visual and hearing impairment making it
difficult for the patient/caregiver to fill out the questionnaires;
(5) suffering other neurological diseases that could have
influenced the diagnosis of dementia; and (6) live in a nursing
home.
The inclusion criteria for controls were: (1) being an
adult of 60 years of age or over; (2) not having memory
complaint reported by either the informant or the elderly person;
(3) completing an Mini Mental State Examination (MMSE)
score of ≥24; (4) having the ability to read and write; and
(5) handing in an informed consent sheet signed by both
the informant and the older person. The exclusion criteria
for this group were: (1) suffering from any acute or severe
chronic illness; and (2) being less alert or suffering from
severe aphasia, impaired vision and/or hearing, which would
make it difficult for the older person to answer any of the
questionnaires.
Analyzed Polymorphisms
The selection of the polymorphisms was performed searching in
the Alzforum database. The search was directed in order to find
SNPs, located in genes that code inflammation-related proteins,
and which had previous reports of association with AD in other
populations.
Fourteen SNPs were selected, which were distributed among
eight genes that code inflammation-related proteins. The selected
genes were: PTGS2 (Ma et al., 2008), CLU (Lambert et al.,
2009), CR1 (Zhang et al., 2010), CRP (Eriksson et al., 2011),
TNF (Ardebili et al., 2011), the pro-inflammatory interleukins
1α (IL-1α, Combarros et al., 2002) and 6 (IL-6, Chen
et al., 2012), and the anti-inflammatory interleukin 10 (IL-
10, Bagnoli et al., 2007). The selected SNPs are listed in
Table 1.
Additionally, in order to perform the ancestry analysis
of the study population, a set of 10 ancestry informative
markers (AIMs) were selected (rs4884, rs2695, rs17203,
rs2862, rs3340, rs722098, rs223830, rs1800498 and rs2814778).
These AIMs are SNPs which frequencies significantly vary
between Amerindian, Caucasian and African populations.
These AIMs have already been tested to accurately
estimate ancestry in populations of Latin American origin
(Salari et al., 2005; Choudhry et al., 2006; Ziv et al.,
2006).
DNA Extraction and Genotyping
Peripheral blood was extracted from all subjects, and was stored
in Vacutainer® tubes with EDTA. Genomic DNA was extracted
from blood using the extraction kit Midi Kit QIAamp® DNA
Blood (Qiagen). The extracted DNA was used to perform real-
time PCR for the 14 inflammation related SNPs and the 10
AIMs. PCR was performed in a 7500 Fast Real Time PCR
System® (Applied Biosystems). SNPs were genotyped using
TaqMan® probes (Applied Biosystems) with real-time PCR
detection.
Statistical Analysis
Ancestry Analysis
The genotypes obtained by the genotyping of the AIMs were
analyzed in order to produce estimates of the proportion in
which each ancestral population is represented in the study
population. To achieve this, LEADMIX (Wang, 2003) and
STRUCTURE (Pritchard et al., 2000) software were required.
For the analysis with LEADMIX, the 10 genotyped AIMs were
used, while the information of the frequency of these AIMs in
ancestral populations was obtained from the database dbSNPs,
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TABLE 1 | SNPs analyzed in the present study.
SNP Chromosome Chromosome position Gene SNP location Alleles
rs20417 1 186681189 PTGS2 −765 Promoter C/G
rs9331888 8 27611345 CLU Exon C/G
rs6656401 1 207518704 CR1 Intron A/G
rs1799724 6 31574705 TNF −850 Promoter G/A
rs1800629 6 31575254 TNF −308 Promoter T/C
rs1800947 1 159713648 CRP Exon C/G
rs1130864 1 159713301 CRP 3′ UTR G/A
rs17561 2 112779646 IL-1 Exon G/T
rs1800795 7 22727026 IL-6 −174 Promoter C/G
rs1800796 7 22726627 IL-6 −572 Pomoter G/C
rs1524107 7 22728600 IL-6 Intron G/A
rs1800871 1 206773289 IL-10 −819 Promoter G/A
rs1800896 1 206773552 IL-10 −1082 Promoter C/T
rs1800872 1 206773062 IL-10 −592 Promoter C/A
available in the National Institute for Health website. Fisher’s
exact test was used to compare proportions between cases and
controls.
For the analysis with STRUCTURE, only seven of the
genotyped AIMs were used (rs4884, rs2695, rs17203, rs2862,
rs3340, rs1800498 and rs2814778). Because the analysis with
STRUCTURE requires individual genotype information from
subjects belonging to the ancestral populations (reference
subjects), a database composed of data collected by Salari et al.
(2005), data from the 1000 Genomes Project (Abecasis et al.,
2010), and data from the study population was used. Reference
subjects for the Caucasian population were Utah residents
of European ancestry, Finnish, English, Spanish, Italians and
Germans. Reference subjects from the African population were
people from Nigeria, Sierra Leone and the Central African
Republic. Because the 1000 Genomes Project lacks information
from the Amerindian population, reference subjects for this
population were taken exclusively from Salari et al. (2005)
and they were Mayan and Native Americans from the Pima,
Cheyenne and Pueblo ethnic groups.
Association Testing
Allele and genotype frequencies were determined using
the SNPStats software (Solé et al., 2006). Departure from
Hardy–Weinberg equilibrium (HWE) was assessed by χ2 test,
using the GenAlEx 6.5 software (Peakall and Smouse, 2012).
For the association testing, estimates of the individual
ancestry proportions obtained from STRUCTUREwere included
along with age and gender in the regression model for odds
ratio calculation in SNPStats. For this analysis, only the values
for Amerindian and African ancestry were included to avoid
collinearity in the model. In order to account for multiple testing,
the Bonferroni correction was applied while interpreting the
significance of the associations found.
Linkage Disequilibrium Analysis
Additionally the level of linkage disequilibrium (LD) among the
selected SNPs was calculated. For this purpose, the Haploview v.
4.2 software was used.
Results
Age and Gender in the Study Population
A total of 194 subjects were genotyped, 94 DAT and 100 controls.
Table 2 presents the distribution of gender among each study
group as well as the mean age for each gender and group.
No significant differences were observed in the distribution
of gender between study groups (p = 0.543). Results from the
Student’s t test comparing the mean age between DAT and
controls not showed significant differences (p = 0.111). Also, we
didn’t find differences when we performed a comparison testing
the mean age of the different genders independently (women p =
0.071, men p = 0.899).
Ancestry Analysis of the Study Population
Ancestry Proportion Estimation in Study Groups
The contribution of each ancestral population in each study
group was calculated using the Bertorelle and Excoffier (1998)
estimator with LEADMIX. Results are shown in Figure 1. As
it can be noted, Amerindian ancestry was represented in a
higher proportion in controls as well as in DAT, followed
closely by Caucasian ancestry, and finally by African ancestry
in a lower proportion. The results of the Fisher’s exact test
showed that there are no significant differences (p = 0.706) in
TABLE 2 | Age and gender in the study population.
Study group Number of women Mean age women (yrs) Number of men Mean age men (yrs) Total mean age
DAT 65 (69%) 76.37 ± 1.11 29 (31%) 74.93 ± 1.68 75.93 ± 0.92
Controls 64 (64%) 73.46 ± 1.15 36 (36%) 74.67 ± 1.29 73.9 ± 0.86
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FIGURE 1 | Ancestry proportions in cases and controls. The
proportions of ancestry in each group of study were estimated in the
LEADMIX software (Wang, 2003) taking the ancestral populations
information of 10 AIMs obtained from the database of the National Institute
for Health website.1 No significant differences were found after the Fisher’s
exact test (p = 0.706).
ancestry proportions between DAT and controls. This result was
corroborated with the analysis in STRUCTURE, which yielded
the ancestry proportion estimates for each study subject; the
estimates were subsequently grouped into a cluster (Figure 2).
Derived from these analyses we conclude that both groups are
genetically homogeneous in ancestry.
Analyzed SNPs and AD Risk
Allele and genotype frequencies of the 14 SNPs were analyzed
(Table 3). Genotypes were assessed for departure from HWE.
Four polymorphisms presented a significant departure in the
FIGURE 2 | Cluster analysis of the three ancestral populations and the
study groups. The triangle obtained from the STRUCTURE software
(Pritchard et al., 2000) allows to observe that the distribution of the individuals
of each study group between the three ancestral clusters is similar.
control group; they were rs6656401 (p = 0.012), rs1799724 (p =
0.013), rs1800795 (p = 0.043) and rs1800871 (p = 0.000). Because
of the deviations, those SNPs were excluded from our replication
study.
In order to adjust for multiple testing, the Bonferroni
correction was applied; according to the calculations, a corrected
p value less than 0.00357 was considered significant. The
association test showed important differences in the rs20417
located in the PTGS2 gene. The presence of GG genotype was
significantly more frequent in the DAT group (OR = 2.89, 95%
CI = 1.41–5.92, p = 0.0028), this could suggest an association with
AD. No significant differences were found between DAT and
controls in the allele frequencies of the rest of the SNPs analyzed
(Table 3).
LD Calculation
The software Haploview was used to measure LD among pairs of
loci, and the r2 an LD parameter was calculated.
Figure 3 shows that the highest values of r2 can be found
between the SNPs rs1800796 and rs1524107 within the IL-6 gene,
and between the SNPs rs1800871 and rs1800872 within the IL-10
gene.
Discussion
This study is focused on the search of genetic risk factors
associated with AD in Mexican population, considering the
ancestry of the population studied and analyzing some of the
main genes related to the inflammatory process observed in AD
patients. Previous studies have identified AD associated variants
in the genes analyzed in this study; nevertheless, until now these
studies have been often limited to the evaluation of variants
within a single gene, or a few genes.
1http://www.ncbi.nlm.nih.gov/SNP
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TABLE 3 | Allelic and genotyping analysis.
SNP Allele Genotype Association with response status p (adjusted by
frequencies frequencies (adjusted by sex + age) sex + age + ancestry)
p OR 95% CI
rs20417 C G CC CG GG
AD 0.08 0.92 0.01 0.14 0.85 0.0018** 2.99 1.47–6.11 <0.0001**
Control 0.19 0.81 0.03 0.32 0.65
rs9331888 G C GG GC CC
AD 0.46 0.54 0.17 0.59 0.24 0.99 1.00 0.52–1.93 0.48
Control 0.53 0.47 0.31 0.44 0.25
rs6656401 A G AA AG GG
AD 0.16 0.84 0.05 0.21 0.73 + + + +
Control 0.2 0.8 0.08 0.24 0.68
rs1799724 A G AA AG GG
AD 0.2 0.8 0.05 0.29 0.66 + + + +
Control 0.32 0.68 0.16 0.33 0.51
rs1800629 T C TT TC CC
AD 0.1 0.9 − 0.19 0.81 0.16 0.56 0.25–1.28 0.7
Control 0.06 0.94 - 0.11 0.89
rs1800947 G C GG GC CC
AD 0.04 0.96 0.01 0.06 0.93 0.76 0.84 0.27–2.62 0.07
Control 0.03 0.97 - 0.06 0.94
rs1130864 A G AA AG GG
AD 0.35 0.65 0.13 0.45 0.43 0.27 1.39 0.77–2.51 0.0008**
Control 0.4 0.6 0.15 0.51 0.34
rs17561 T G TT TG GG
AD 0.26 0.74 0.06 0.38 0.55 0.31 1.34 0.76–2.38 0.52
Control 0.3 0.7 0.97 0.45 0.48
rs1800795 G C GG GC CC
AD 0.18 0.82 0.05 0.24 0.7 + + + +
Control 0.1 0.9 0.03 0.15 0.82
rs1800796 C G CC CG GG
AD 0.32 0.68 0.09 0.47 0.45 0.69 1.13 0.63–2.01 0.27
Control 0.36 0.64 0.16 0.41 0.43
rs1524107 A G AA AG GG
AD 0.31 0.69 0.09 0.46 0.46 0.88 1.04 0.59–1.85 0.02
Control 0.34 0.66 0.15 0.39 0.46
rs1800871 A G AA AG GG
AD 0.44 0.56 0.21 0.46 0.33 0.87 1.05 0.57–1.93 0.87
Control 0.42 0.57 0.17 0.51 0.32
rs1800896 T C TT TC CC
AD 0.46 0.54 - 0.91 0.09 + + + +
Control 0.46 0.54 - 0.91 0.09
rs1800872 A C AA AC CC
AD 0.39 0.61 0.16 0.46 0.38 0.4 1.29 0.71–2.34 0.33
Control 0.42 0.58 0.16 0.52 0.32
** After Bonferroni correction (p = 0.00357) only the rs20417, was significant. + Excluded because of significant departure from Hardy-Weinberg in controls.
HWE has been proposed as a routine evaluation in
case-control genetic association studies. Genotyping errors,
population stratification, a small sample size and non-random
mating generally contribute to departures on this equilibrium
and favor false associations (Salanti et al., 2005; Wang and Shete,
2012). Based in this fact, we omit four SNPs from the association
test, because they present a HWE departure in control group.
Another resource that we used for reducing the probability
of obtaining false positives in the statistical analysis of the
association test was the correction for multiple testing.
In this study, the homozygous genotype GG in the
SNP rs20417, was overrepresented in AD patients and
underrepresented in controls in the PTGS2 gene. These
results essentially match with the results obtained by Abdullah
et al. (2006) and Listì et al. (2010), who found the C allele is
linked to a decrease in the risk of developing the disease. Our
data suggest that GG polymorphism in PTGS2 could be a risk
factor for AD in Mexican population.
PTGS2 is expressed in neurons of the neocortex and
hippocampus under normal physiological conditions, suggesting
its essential role in normal neuronal function. COX-2 catalyzes
the formation of PG’s, which are well-known inflammatory
mediators. In fact, during some pathological conditions it
can be expressed in microglia and astrocytes. Several authors
have noted that COX2 is involved in several neurological
diseases such as Parkinson’s disease (Teismann et al., 2003),
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FIGURE 3 | Linkage Disequilibrium (LD). The images derived from the
Haploview software (Barrett et al., 2005) display the r2 values of LD. High
values of r2 (depicted in dark gray) were presented among SNPs in IL-6 (A)
and IL-10 (B).
amyotrophic lateral sclerosis (Almer et al., 2001), schizophrenia
(Müller et al., 2004) and AD (Pasinetti and Aisen, 1998;
Hoozemans and O’Banion, 2005). In 1999, Yasojima et al.
reported that COX-2 was substantially upregulated in affected
areas of AD brain, this dominant upregulation in neurons could
reflect a defensive response of the neurons to stress (Yasojima
et al., 1999). However, the chronic expression of COX-2 may
contribute to aggravate stress through the generation of free
radicals causing oxidative stress and neurotoxicity. COX-2 in
the CNS may enhance neuritic plaque formation by means
of the production of PGE2, which can induce the expression
of the Aβ precursor protein (APP). In turn, the presence of
NPs can increase the expression of COX-2 (Nogawa et al.,
2003).
Therefore, the GG genotype in the SNP rs20417 that
displayed association with AD in this study might have an
effect over the gene expression rate, resulting in an alteration
of protein concentrations. This might exert an influence over
the mechanisms of Aβ synthesis, thus contributing to modify
the risk of developing the disease. Conversely, the C allele has
a reduced promoter activity, suggesting that lower promoter
activity of COX-2 gene might be protective for AD. In the
rest of the analyzed SNPs no significant differences were found
when comparing the allele or genotype frequencies between
AD patients and controls. These results contradict previous
reports in which an association between these SNPs and the
risk of developing AD was found (Bonafè et al., 2001; Brull
et al., 2001; Combarros et al., 2002, 2009; Flex et al., 2004;
Laws et al., 2005; Bagnoli et al., 2007; van Oijen et al., 2007;
Harold et al., 2009; Lambert et al., 2009; Jun et al., 2010; Zhang
et al., 2010; Hu et al., 2011; Chen et al., 2012; Shen et al.,
2014).
We also found two regions of high LD, one in the IL-
6 gene and another in the IL-10 gene. These results and the
HWE deviations presented in both genes, suggest that future
genetic association studies focused on those regions should be
done using a larger sample size in order to clarify a possible
association with AD in the Mexican population as was observed
principally in Caucasian populations (Bonafè et al., 2001; Brull
et al., 2001; Bagnoli et al., 2007; Combarros et al., 2009; Chen
et al., 2012).
Most inconsistencies in genetic association studies, are
probably due to ethnic differences among analyzed populations
(Dixon et al., 2011), because populations with differences
in genetic ancestry should not be extrapolated. In order to
validate our results, we focused in the stratification of our
samples, which is a confounding factor that could partly explain
the relative lack of replication across populations (Thomas
and Witte, 2002). To avoid the effects of stratification we
estimate the ancestry proportion in each study group and
all the groups were included with age and gender in the
regression model for odds ratio calculation in SNPStats. The
inclusion of the adjustment for ancestry in the association
testing ensures that the contribution of each ancestral population
is homogeneous between AD patients and controls and it
does not play a confounding role in the analysis (Epstein
et al., 2007). The ancestry proportion estimates obtained
in this study are comparable with previous reports in the
Mexican population, observed by Juárez-Cedillo et al. (2008)
using 15 short tandem repeats (STRs), and by Rangel-
Villalobos et al. (2009), using 12 Y-chromosome STRs.
Therefore these results corroborate the validity of the AIMs
selected.
It is important to mention that this is the first study in
Mexican population that considers the analysis of ancestry in AD
patients in which it was possible to find that the presence of the
GG genotype in the SNP rs20417 displayed an association with
AD patients in our population. We consider the association of
rs20417 genotype GG was adequate based on confidence interval
(1.47–6.11). In the same way after the correction by ancestry,
another polymorphism (rs1130864) showed a significant p value
(0.0008), however this association is questionable because the IC
= 0.77–2.51. Although this could be a pilot study, it is essential
to increase the sample size to support statistical power. Also,
it is important to conduct more extensive studies involving
genes related to the COX2 metabolism. This will establish
possible mechanisms involved in the pathological process of the
disease.
Conclusions
In summary, this is the first study in Mexican population
that considers the analysis of ancestry in AD patients. Our
results showed that the rs20417 SNP in the PTGS2 gene
presented differences in its allele and genotype frequencies
pointing at the G allele and the GG genotype, and it could
be considered as a risk factor for AD in Mexican patients.
These results manifest the relevance of the role that COX-2
is playing in the pathological mechanisms that result in the
development of AD. Ancestry analysis showed that there were
not significant differences in AD patients and controls with
Frontiers in Cellular Neuroscience | www.frontiersin.org 7 May 2015 | Volume 9 | Article 148
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respect to genetic ancestry, corroborating the validity of the
associations found.
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